Alcon announces closing of acquisition of Belkin Vision

News
Article

Belkin Vision is the developer of Vision Eagle direct selective laser trabeculoplasty technology.

Business meeting in office Image Credit: AdobeStock/alfa27

Image Credit: AdobeStock/alfa27

Alcon has announced completion of its acquisition of Belkin Vision, developer of the Belkin Vision Eagle direct selective laser trabeculoplasty (DSLT) for the treatment of glaucoma. The companies have agreed to a total upfront consideration of $81 million USD, including a cash payment of approximately $65 million, according to a news release. The deal also includes the potential for up to $385 million in payments, which is contingent on sales-based milestones.1

“As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of SLT in the glaucoma treatment paradigm,” said Sean Clark, president of Global Surgical Franchise at Alcon, in the release. “We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”

The acquisition includes the DSLT technology, which works in a similar fashion to traditional SLT by delivering laser energy to the trabecular meshwork. DSLT technology, however, includes proprietary eye-tracking technology for accurate, automated treatment delivery through the limbus, which eliminates the needs for a gonio lens or manual aiming, according to the release.1

“Despite ample evidence for SLT as primary therapy in glaucoma treatment, practical challenges limit availability to many patients who could benefit from it,” said Nathan M. Radcliffe, MD, in the release. “DSLT will have a profound impact on laser-first, helping to overcome these barriers and meaningfully improve access to laser therapy — shifting doctor and patient perceptions around efficiency and comfort.”

Belkin’s DSLT technology has been approved in the EU and UK, and has receive 510(k) clearance from the US FDA, but is not available yet in the US. Alcon plans to continue supplying DSLT technology in the EU and UK and aims to have the device available to eye care providers in the US by the end of 2024.1

References:
  1. Alcon completes acquisition of Belkin Vision, expanding glaucoma portfolio with direct selective laser trabeculoplasty (DSLT) device. Alcon. July 1, 2024. Accessed July 2, 2024. https://www.alcon.com/media-release/alcon-completes-acquisition-belkin-vision-expanding-glaucoma-portfolio-direct
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.